

## CHANGE OF DIRECTOR'S INTERESTS

---

Attached is an Appendix 3Y Notice for Mr David Brookes which is in relation to the acquisition by Mr Brookes of an interest in 2,500,000 shares on 8 October 2021 pursuant to the public offering conducted by the Company to raise \$4 million.

The intention of Mr Brookes to acquire an interest in these shares was disclosed at page 92 of the Replacement Prospectus dated 9 September 2021, however due to an administrative oversight, an Appendix 3Y relating to the acquisition of those shares was not lodged.

The Company has reviewed its procedures to ensure such an oversight does not re-occur.

This announcement has been authorised by the Company Secretary.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS)</b>
<b>ABN</b>	<b>45 101 955 088</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr David Brookes
<b>Date of last notice</b>	27 September 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Dr. D. L. Brookes Personal Superannuation Fund (of which Dr Brookes is a beneficiary)  Dahlbrook Family Trust (of which Dr Brookes is appointer of the Trust)
<b>Date of change</b>	8 October 2021
<b>No. of securities held prior to change</b>	500,000 unlisted share options  2,401,250 fully paid ordinary shares
<b>Number acquired</b>	2,500,000 fully paid ordinary shares
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$0.04 per share
<b>No. of securities held after change</b>	500,000 unlisted share options  4,901,250 fully paid ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares acquired at \$0.04 per share pursuant to the Public Offer described in the Replacement Prospectus dated 9 September 2021.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

+ See chapter 19 for defined terms.

For personal use only